Rationale: Previous work indicates that ivacaftor improves cystic fibrosis transmembrane conductance regulator (CFTR) activity and lung function in people with cystic fibrosis and G551D-CFTR mutations but does not reduce density of bacteria or markers of inflammation in the airway. These findings raise the possibility that infection and inflammation may progress independently of CFTR activity once cystic fibrosis lung disease is established.
Cystic fibrosis (CF) is caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR), a membrane anion channel (1) . The most important clinical manifestation of CF is lung disease, and respiratory failure is the major cause of death in people with CF (2) . CF lung disease is a consequence of a series of events beginning with host defense defects caused by CFTR dysfunction. Impaired host defenses lead to chronic airway infection and inflammation, and eventually to lung injury and respiratory failure (1) .
Intensive research has been directed toward developing agents that improve CFTR function, with the hope that correcting the basic defect would reverse disease. The first drug approved, ivacaftor, markedly improves CFTR activity in people with G551D-CFTR mutations (3) . Indeed sweat chloride measurements (which reflect CFTR activity) approach normal levels almost immediately on treatment (4) .
Despite the marked increases in CFTR activity, lung function improves only modestly with ivacaftor (3). Furthermore, the two studies that investigated ivacaftor's effects on the concentration of bacteria and inflammatory markers in airway secretions did not detect improvements in these parameters. The GOAL (G551D Observation-AL) study evaluated 14 subjects and found sputum pathogen abundance and measures of inflammation generally unchanged after ivacaftor (5) . A smaller study of three pediatric subjects treated with ivacaftor produced similar results (6) .
It is notable that an epidemiologic analysis of patient registry records found a decreased prevalence of Pseudomonas aeruginosa-positive cultures in subjects in the year after ivacaftor initiation (7) . However, most of the decreased prevalence occurred in subjects who were not chronically infected with P. aeruginosa, and reductions in P. aeruginosa-positive cultures were not associated with improved lung function (7) .
Several mechanisms could explain why reduced concentrations of bacteria and inflammatory markers were not detected after ivacaftor treatment. One possibility is that infection and inflammation progress independently of CFTR function after disease is established. For example, the presence of bronchiectasis, submucosal gland hypertrophy, and epithelial injury could sustain infection and inflammation even after CFTR function is normalized. It is also possible that changes in microbiologic and inflammatory parameters would be apparent if different airway sampling methods or assays were used, or if subjects had been studied at different disease stages.
Understanding the relationship between CFTR activity, infection, and inflammation is important because it could improve knowledge of the pathogenesis of chronic CF lung disease. In addition, if infection and inflammation become uncoupled from CFTR activity in established disease, drugs targeting CFTR may need to be initiated very early in life, or used in combination with agents that suppress infection and inflammation. Here we studied airway microbiology, inflammation, and clinical parameters in adult subjects with G551D-CFTR mutations and chronic airway infections before and after initiation of ivacaftor to better understand the new state of disease after CFTR function is restored. Some of the results of these studies have been previously reported in the form of an abstract (8) .
Methods Study Design and Description of Subjects
We prospectively studied 12 subjects with CF and one or more G551D-CFTR alleles ( Table 1) . Eight of the 12 subjects were chronically infected with P. aeruginosa, two were chronically infected with Burkholderia species, and two were chronically infected with Staphylococcus aureus (see Table E1 in the online supplement). The subjects' median age was 29.5 years (range, 22-57), and 9 of 12 subjects were female. FEV 1 ranged from 34% to 101% predicted, with a mean FEV 1% predicted of 64.2 (Table 1) .
Clinical and Sputum Measurements
Sweat chloride levels and lung function were measured using standard methods. Chest computed tomography (CT) scans were performed before and approximately 1 year after starting ivacaftor, and scored by an experienced thoracic radiologist. Quantitative culture, polymerase chain reaction (PCR), 16S rRNA gene sequencing, and measurements of inflammatory markers were performed on spontaneously expectorated sputum. Multilocus sequence typing (MLST) and pulsed field gel electrophoresis (PFGE) fingerprinting were performed on cultured P. aeruginosa.
Statistical Analyses
Paired Student's t tests were used, and twosided P values reported. Repeated measures analysis of variance was used to test culture, PCR, sequencing, and inflammatory marker data. Piecewise, mixed-effect linear regression models (9) were used to test FEV 1 , bacterial, and diversity index slope changes. Correlation analyses were performed using Spearman correlation coefficient. SAS version 9.4 (SAS Institute, Cary, NC) was used for all analyses. Methods are described in detail in the METHODS section of the online supplement.
At a Glance Commentary
Scientific Knowledge on the Subject: Drugs that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity can improve lung function and health in people with cystic fibrosis. However, it is unclear whether improved CFTR activity affects airway infection and inflammation.
What This Study Adds to the Field: We found that the CFTRcorrecting drug ivacaftor markedly reduced sputum Pseudomonas aeruginosa concentrations and markers of inflammation during the first treatment year in subjects with chronic P. aeruginosa infections. However, no subject eradicated his or her infecting P. aeruginosa strain, and after the first year P. aeruginosa density rebounded. The finding that chronic infection persists and may rebound after CFTR function is corrected suggests that measures to control infection may be required to realize the full benefits of CFTRtargeting treatments.
Results
Ivacaftor Produced Rapid Improvements in Sweat Chloride and FEV 1 We measured sweat chloride concentrations and lung function to verify that our cohort experienced typical responses to ivacaftor. Sweat chloride concentrations were markedly reduced after 2 days of treatment ( Figure 1A ), indicating improved CFTR function. Lung function (FEV 1 ) also improved after 2 days (mean increase, 0.29 L; 95% confidence interval [CI], 0.14-0.45; P = 0.0016), with continued improvements on Day 7 (additional increase from Day 2 of 0.17 L; 95% CI, 0.0002-0.33; P = 0.07) ( Figure 1B) , and Day 400 (additional increase from Day 7 of 0.16 L; 95% CI, 20.03 to 0.34; P = 0.09) ( Figure 1C) .
We also analyzed all clinically obtained FEV 1 values; adjusted the values for age, sex, and height; and found the rate of change in FEV 1 (the FEV 1 slope) in the 2 years after ivacaftor was significantly improved compared with the 2 years before (0.004 L/mo; 95% CI, 20.0004 to 0.008; vs. 20.007 L/mo; 95% CI, 20.0094 to 20.0053) (P , 0.001) ( Figure 1D ). Thus, ivacaftor produced rapid and sustained improvements in lung function in study subjects (also described in References 10 and 11).
Ivacaftor Markedly Reduced Sputum P. aeruginosa in the First Treatment Week
Reducing airway P. aeruginosa is a key therapeutic objective in CF (12, 13) . Eight of the 12 subjects were chronically infected with P. aeruginosa (see Table E1 ), and in these subjects sputum P. aeruginosa CFUs began to decrease at Day 2 ( Figure 2A) . By Day 7, average sputum P. aeruginosa CFUs had declined by 10-fold (1.06 log 10 CFU; 95% CI, 21.79 to 20.32; P = 0.012) (Figure 2A ). It was notable that even though subjects' pretreatment sputum P. aeruginosa concentrations differed by more than 4 logs (10 5 -10 9 CFUs/ml), all subjects demonstrated marked declines in P. aeruginosa during the first 7 days of treatment ( Figure 2A ). We used quantitative PCR (qPCR) measurements of P. aeruginosa genome copies to independently investigate ivacaftor-induced changes, and again found significant reductions during the first treatment week ( Figure 2C ). We measured long-term changes in sputum P. aeruginosa and found continued declines after Day 7. Average P. aeruginosa CFU counts declined by 1.67 log 10 CFU/ml (95% CI, 22.39 to 20.96; P = 0.006) ( Figure 2B ) and DNA-based measurements declined by 1.19 log 10 genome/g (95% CI, 21.80 to 20.59; P = 0.01) by Day 210 ( Figure 2D ). Although some subjects were unable to spontaneously expectorate at some visits, none of the chronically infected subjects became consistently P. aeruginosa-culture negative.
P. aeruginosa Counts Rebounded in the Second Year of Treatment
We measured sputum P. aeruginosa density for as long as 975 days, and noted that after Day 210, sputum P. aeruginosa CFU counts stopped declining and began to increase ( Figure 2B ). Mean P. aeruginosa density decreased with a slope of 20.20 log CFU/mo (95% CI, 20.28 to 20.12) until Day 210 then the slope significantly changed (P , 0.0001) to 1 0.04 log CFU/mo (95% CI, 0.014-0.069) over the remaining study period ( Figure 2E ). Increases after Day 210 were noted in six out of seven subjects (Figures 2B) (one P. aeruginosa-infected subject was lost to follow-up). The clinical implication of these increases is unclear (see DISCUSSION).
Subjects Remained Persistently Infected with Their Initial P. aeruginosa Strain Continued infection could be explained if the P. aeruginosa strains present before treatment persisted, or if preexisting strains were cleared and new infection developed. We used three methods to distinguish between these possibilities using sputum samples obtained before, and at the latest time point available after treatment (typically Day 800 or 975). Two of the methods genotyped P. aeruginosa in sputum at a population level, and thus may provide a more comprehensive analysis than studies on individual isolates. We also performed confirmatory studies using a conventional approach on individual isolates.
For the first method, we cultured sputum obtained before and after treatment, picked 96 P. aeruginosa colonies from each sample, and pooled and sequenced them. The high-quality reads that mapped to the seven established P. aeruginosa MLST gene loci were used to generate a consensus sequence that represented the most prominent allele in each population. The consensus sequence was then assigned an MLST type using the P. aeruginosa MLST database (14) .
As shown in Figure 3A , the same consensus MLST type was identified before ORIGINAL ARTICLE and after treatment in each subject. Two subjects living in the same household were infected by P. aeruginosa with the same consensus MLST type, whereas other subjects were infected by different types. Notably, in three cases (subjects 4, 5, and 9) the before and after treatment consensus sequence of one MLST loci (the acs gene fragment) mapped to different alleles (see Figure E1 ). However, this ambiguity did not result in different MLST types. Isolates from these subjects were analyzed further (see below). The second method exploited the allelic variation that evolves within clonally related P. aeruginosa populations infecting subjects with CF (15) (16) (17) (18) . We used the high-quality reads from the 96 isolate pools sequenced at early and late time points (described previously) to measure allele variations at every base of all seven MLST loci. We then counted the number of allele frequency changes between early and late isolate pools from each subject, and compared the results to allele frequency differences between P. aeruginosa isolate pools from different subjects in the cohort as control subjects.
As shown in Figure 3B and Figure E2 , early and late isolate pools from each subject exhibited far fewer allele frequency differences than isolate pools from different subjects (P , 0.0001). . Note that the graph includes 4 years of data, and the x-axis is drawn to scale. Thus it appears that the Day 0, 2, and 7 measurements for FEV 1 all fall near the y-axis. The table lists preivacaftor and postivacaftor subject-specific FEV 1 slope estimates (L/mo), with negative slopes in red, positive slopes in bright green, and slopes that were improved but still negative after ivacaftor in pale green.
Finally, we picked individual P. aeruginosa isolates from the sputum of the three subjects for whom the consensus acs MLST locus sequence showed ambiguity (subjects 4, 5, and 9), and performed conventional PFGE genotyping. PFGE showed that randomly selected isolates from the early and late time points were indeed clonally related ( Figure 3C ; see Figure E3 ). Taken together, these analyses indicate that P. aeruginosa strains present before treatment persisted after treatment. However, the findings do not exclude the possibility that additional strains (that were not captured in the 96 isolates sampled) were also present in sputum at low relative abundance.
Ivacaftor Changed the Relative Abundance of Sputum Microbiota
We measured the relative abundance of sputum microbiota by amplifying, sequencing, and performing taxonomic classification of bacterial 16S ribosomal RNA gene sequences (16S rDNA), focusing on the subjects chronically infected with P. aeruginosa as they were followed longterm. Most of the non-P. aeruginosa taxa found in these samples (including Streptococcus, Prevotella, Veillonella, and other taxa) are highly abundant in the oropharynx (19) (20) (21) , and they have not historically been considered CF pathogens (we call them nonconventional organisms later). Inspection of individual subjects' sputum microbiota profiles suggested that changes in the relative abundance of P. aeruginosa were generally accompanied by reciprocal changes in the relative abundance of nonconventional organisms and in the overall diversity of microbiota present ( Figure 4 ).
To explore this further, we calculated indices of microbial diversity, including microbial richness (the number of identified taxa), evenness (how similar the abundances of the taxa were), and the Shannon diversity index (which accounts for both richness and evenness). Average changes in the diversity indices roughly exhibited patterns opposite to those of both P. aeruginosa absolute and relative abundance. Average measurements of P. aeruginosa absolute ( Figure 2E ) and relative ( Figure 5A ) abundance declined during the first year of treatment, and then rebounded, whereas the microbial diversity indices generally increased in the first year, and then decreased ( Figures 5B-5D ). We estimated the change in microbial diversity indices over time using linear regression analysis, and found that microbial richness and Shannon diversity measures increased in the first year (i.e., showed positive slopes), and then exhibited statistically significant decreases in slopes thereafter (P , 0.05) (see Table E2 ). Figure 3 . Pseudomonas aeruginosa strains infecting subjects persist after treatment. (A) Multilocus sequence typing (MLST) analysis of consensus sequences before and after treatment. Ninety-six P. aeruginosa isolates collected at the indicated time points were pooled, sequenced, and consensus MLST sequences were generated. The early and late sputum sample of each subject generated the same consensus MLST sequence type. *Subjects in whom the acs loci showed ambiguity (see Figure E1 ). (B) Changes in MLST allele frequency in P. aeruginosa isolate pools collected before and after treatment. P. aeruginosa isolate pools from before and after treatment from individual subjects (top 8 graphs) showed far fewer differences than pools from different subjects (bottom 2 graphs) (P , 0.0001). See Figure E2 for data from other subjects. (C) Pulsed-field gel electrophoresis results of randomly selected isolates before (left side of each column) and after (right side of each column) treatment from subjects 4, 5, and 9 (see also Figure E3 ). All isolates from individual subjects were .95% related (see Figure E3 ).
Ivacaftor Did Not Change the Absolute Abundance of Nonconventional Organisms
Previous work measuring airway clearance using radiotracer methods (5), and the rapidity with which P. aeruginosa declined (Figure 2) , suggest improved mucociliary clearance may be a major therapeutic effect of ivacaftor. It seems likely that mucociliary clearance would remove all species of airway bacteria indiscriminately. Thus we found it perplexing that pattern of change in P. aeruginosa abundance was roughly opposite that seen with the microbial diversity indices. Two explanations for these findings seem plausible. One possibility is that ivacaftor produces opposing effects on the airway abundance of P. aeruginosa relative to other organisms. A second possibility is that the reciprocal changes in P. aeruginosa abundance and the microbial diversity indices are primarily a consequence of the absolute reductions in P. aeruginosa we observed. This is possible because the diversity indices are calculated from relative abundance data. Thus, changes in the absolute abundance of one organism could lead to changes in the relative abundance of others even if the other organisms show no change in absolute abundance. In other words, relative abundance totals must equal 100%.
We used two approaches to explore these possibilities further. First, we used qPCR to directly measure the absolute abundance of Streptococcus and Prevotella, because they were the most abundant nonconventional organisms in most subjects' initial sputum samples (Prevotella was the most abundant nonconventional organism in 9 of 12 subjects and Streptococcus in 2 of 12 subjects) (Figure 4) . Furthermore, combined relative abundance of Streptococcus and Prevotella showed roughly the opposite pattern change seen with P. aeruginosa (compare Figure E4 and Figure 5A) ; increasing in the first year, and then decreasing thereafter (P , 0.05) (see Table E3 ). However, direct PCR measurements showed that neither Streptococcus nor Prevotella significantly changed in absolute abundance during the study period (Figures 6A-6D Figure 4 . Ivacaftor treatment changes the relative abundance of sputum microbiota. The colored segments of each bar represent the proportion of 16S rDNA reads mapping to the indicated bacterial taxa. The key identifies taxa present at greater than or equal to 0.5% average abundance. Lowerabundance taxa are identified in Table E19 . *Subjects that were not chronically infected with Pseudomonas aeruginosa based on cultures used for clinical care.
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Second, we compared changes in the absolute abundance of all bacteria and of Pseudomonas species by qPCR. This analysis is informative because if the magnitude of Pseudomonas changes exceeded those of total bacteria, changes in the combined relative abundance of non-Pseudomonas organisms and microbial diversity could be attributable to Pseudomonas declines. Indeed at every time point, P. aeruginosa changed to a greater extent than total bacteria ( Figure 6E ). Taken together, these findings suggest that in the P. aeruginosa-infected subjects, the observed changes in the combined relative abundance of non-P. aeruginosa organisms and in diversity indices were primarily a consequence of the marked decline in the absolute abundance of sputum P. aeruginosa (see DISCUSSION).
Microbiologic Effects of Ivacaftor on Subjects without Chronic P. aeruginosa Infections
Sputum samples from the four non-Pseudomonas-infected subjects were primarily collected during the first study week. Although the number of subjects was very small, and none of the microbiologic changes achieved statistical significance, some interesting changes were noted. For example, as for the P. aeruginosa-infected subjects, total sputum bacterial density (measured by qPCR) seemed to decline in all four non-Pseudomonas-infected subjects during the first week of treatment (see Figure E5A ) (P = nonsignificant). Furthermore, the relative abundance of Burkholderia species seemed to decline in the two subjects with chronic Burkholderia infections (P = nonsignificant) (see Figure  E5B ). The two subjects with Staphylococcusdominated infections showed no decreases in Staphylococcus relative abundance (see Figure E5B ). Additional work is needed to determine if the changes identified in these subjects represent reproducible findings.
Ivacaftor Caused Sustained Reduction in Airway Inflammation
We measured sputum neutrophil elastase, IL-8, and IL-1b using ELISA and found rapid and significant reductions during the first treatment week (P , 0.05) ( Figures   7A-7C ) in the entire cohort (i.e., P. aeruginosa-infected and -uninfected subjects considered together). In the P. aeruginosa-infected subjects who we followed long term, these three markers continued to decline over the next 2 years ( Figures 7A-7C) , and all subjects experienced at least a 10-fold decrease by Day 600 (P , 0.005).
To independently gauge inflammation, we measured inflammatory proteins in sputum supernatants using mass spectrometry and detected decreases in neutrophil elastase (P = 0.00003), arginase-1 (P = 0.03), myeloperoxidase (P = 0.003), and calprotectin (S100A8 [P = 0.02] and S100A9 [P = 0.03]) after 1 week of ivacaftor ( Figure 7D ). We note that we did not apply corrections for multiple comparisons to the analysis of the inflammatory markers (see DISCUSSION).
We also separately analyzed inflammatory marker data from the subjects not infected with P. aeruginosa to investigate whether ivacaftor decreased inflammation in these subjects. Although the number of subjects was very small, we found that IL-1b decreased significantly at 1 week (see Figure E6 ). Additional work is needed to determine if ivacaftor treatment consistently reduces inflammation in non-P. aeruginosa infected subjects.
Ivacaftor Improved Chest CT Scans
We measured radiographic changes in lung disease using Brody scoring (22) of inspiratory and expiratory chest CT scans before and 1 year after treatment. Brody scores measure bronchiectasis, mucous plugging, peribronchial thickening, air trapping, and parenchymal damage; higher scores indicate more disease.
Seven of the 12 subjects presented at 1 year to undergo follow-up CT scans. The subjects who presented for CT scans exhibited similar demographic and disease characteristics as those who did not (see Table E4 ). Although the findings should be interpreted with caution because of the small sample size, we found total Brody scores decreased in four subjects, unchanged in two, and increased in one subject, with the average change trending toward improvement ( Figure 8A ) (P = 0.12). Because some Brody score parameters may be reversible, whereas others may not, we examined individual parameters and found significant improvements in mucous plugging (P = 0.012) and a trend toward Table E2 shows linear regression analysis indicating that richness and Shannon diversity showed positive slopes in the first year, and significant decreases in slopes thereafter (P , 0.05).
improvements in peribronchial thickening (P = 0.091) (Figures 8B-8D ; see Table E5 ).
Correlations between Measured Parameters
Although the small size of this study was not conducive to multiple comparisons corrections, we performed exploratory analyses to identify correlations between measured parameters. Tables showing   correlations are provided in the online  supplement (see Tables E6-E15) . Additional work is needed to formally test the observed associations.
Discussion
In contrast to prior studies (5, 6), we found that pharmacologic restoration of CFTR activity produced rapid and marked decreases in the sputum abundance of bacteria, particularly the key CF pathogen P. aeruginosa, and reduced airway inflammation. Sputum P. aeruginosa CFUs decreased by more than 60-fold in the first week of treatment, and reductions were sustained for approximately 7 months. Key inflammatory markers showed approximately fivefold reductions in the first week, with further declines over time. These changes were accompanied by long-term improvements in the rate of lung function decline (FEV 1 slope), and improvements in some radiographic measurements of lung disease. However, restoring CFTR function did not eradicate chronic P. aeruginosa infection, and P. aeruginosa counts rebounded significantly in the second year of treatment. Next we discuss the limitations, strengths, and implications of our findings.
Study Limitations and Strengths
This study has several limitations. First, it is possible that some parameters may have changed because of off-target drug effects. Most relevant to our work is ivacaftor's reported antimicrobial activity. It is possible that the early declines and late increases in P. aeruginosa could reflect initial sensitivity and subsequent resistance to the direct antimicrobial effects of ivacaftor. However, ivacaftor is relatively impotent against P. aeruginosa in vitro (23), and seems unlikely that clinically achievable concentrations would produce sustained approximately 100-to-1,000-fold reductions in P. aeruginosa density.
Second, we did not have a control group, so responses could be a consequence of study participation rather than treatment. We think this unlikely, because control groups in other CF studies have not experienced improvements in infection, inflammation, or lung function in the range of those found here (3, 24) . Third, we were not able to measure the effect of ivacaftor on clinical events, such as exacerbations or long-term antibiotic use, and we did not collect treatment adherence data. Fourth, we note that the DNA-based measurements used do not distinguish live from dead bacteria. Finally, the small study size limited our ability to detect subtle changes or associations. In particular, correlations between parameters were not corrected 
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for multiple comparisons, and we consider those analyses exploratory. Our study also had strengths that reduced variability, improved our ability to detect changes, and increased confidence in the results. The high prevalence of G551D-CFTR mutations in Ireland enabled us to study subjects at one center. Subjects initiated treatment during the same week, so visits were synchronized, and specimens were collected and processed by the same personnel in one laboratory. Each subject served as their own control and was studied at very early and late time points, from 48 hours to almost 1,000 days after treatment. Because of these factors and the magnitude of the responses, many changes reached statistical significance despite the small sample size.
We also note that key conclusions are supported by independent measurements. The finding that ivacaftor produced marked reductions in sputum P. aeruginosa during the first year was supported by culture and DNA-based measurements. The finding that ivacaftor produced marked reductions in airway inflammation was supported both by ELISA and proteomicsbased measurements. Our interpretation that the observed changes in microbial diversity indices were likely a consequence of P. aeruginosa reductions was also supported by two findings. First, direct PCR assays showed no significant changes in the absolute abundance of the two dominant non-Pseudomonas taxa detected in subjects' sputum (Prevotella and Streptococcus). Second, we found that absolute abundance of P. aeruginosa changed to greater extent than total bacteria. Thus, the reciprocal changes noted in non-P. aeruginosa organisms and microbial diversity are likely to be a consequence of changes in P. aeruginosa.
Explanations for Discordance with Previous Studies
Our findings differ from prior studies (5, 6) that did not detect reductions in the density of sputum bacteria, airway pathogens, or airway inflammation after ivacaftor. We speculate that differences in study design and subjects' infection characteristics are responsible. For example, although our study and GOAL (5) studied infection and inflammation in similar numbers of subjects, fewer GOAL subjects had chronic P. aeruginosa infections (40 vs. 66%). None of the three subjects in the study by Bernarde and coworkers (6) was chronically infected with P. aeruginosa. The prevalence of chronic P. aeruginosa infections could be an important factor, because changes in P. aeruginosa density were the most robust microbiologic finding in our study, and seemed to drive other microbiologic changes we observed, including changes in the combined relative abundance of non-Pseudomonas organisms, and changes in microbial diversity indices. Technical differences may have also affected results. For example, GOAL studied induced sputum, whereas we studied spontaneously expectorated samples. We also fractionated sputum into pellets and supernatants immediately to measure inflammation, whereas GOAL froze sputum. Thawing-induced cell lysis could release cytokines and obscure changes. Finally, GOAL involved multiple study sites, which could affect measurements.
Why Did P. aeruginosa and Other Bacteria Show Reciprocal Changes?
Measurements on the P. aeruginosainfected subjects suggest that changes in the relative abundance of non-Pseudomonas organisms are likely a consequence of absolute changes in P. aeruginosa, rather than being caused by absolute changes in abundance of other bacteria.
These findings could be explained if ivacaftor somehow preferentially affected airway P. aeruginosa, and had relatively minor effects on other organisms. Another possibility relates to the fact that expectorated sputum contains secretions from the lower airways and saliva, and perhaps other sources. This is important because many nonconventional organisms detected in CF sputum (including Prevotella, Streptococcus, and Veillonella species) are highly abundant in saliva, and salivary bacterial concentrations rival those found in sputum (19) (20) (21) . Thus, if ivacaftor changed P. aeruginosa density in lower airway secretions, and the extent of salivary contamination was unchanged, the relative abundance of nonconventional organisms in sputum and microbial diversity indices could exhibit reciprocal changes as a secondary effect.
It was notable that that total bacterial abundance seemed to decrease in the subjects who were not chronically infected with P. aeruginosa, as it did in P. aeruginosa-infected subjects. However, the number of subjects not chronically infected with P. aeruginosa was very small, data were only available for the first treatment week, and changes in these subjects did not reach statistical significance. If the trends observed in the non-P. aeruginosa infected subjects reflect real changes, the total bacterial abundance reductions could have been driven by declines in the conventional pathogens present (e.g., Burkholderia and Staphylococcus species). It is also possible that ivacaftor reduced nonconventional organisms in these subjects. Additional work is needed to understand the differential responses of conventional and nonconventional organisms to ivacaftor. The significant increase in sputum P. aeruginosa CFUs we observed during the second treatment year is concerning. It is possible that improved health causes reduced adherence to ivacaftor or other treatments (25) , and unfortunately treatment adherence data were not collected. A more worrisome possibility is suggested by studies showing that P. aeruginosa genetically diversifies during 
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CF infections (15) (16) (17) (18) . Therefore, P. aeruginosa genetic variants could arise that are capable of surviving or even thriving after CFTR is restored. If adapted P. aeruginosa variants do rebound, sustained health improvements may require the combined use of CFTR-restoring and antiinfective treatments. n Author disclosures are available with the text of this article at www.atsjournals.org.
